Q32 Bio Inc.
For the period ended Sep 30, 2026. Filed Sep 30, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Sep 30, 2026 · Filed Sep 30, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Bempikibart Development Program in AA:
Bempikibart Development Program in AA:
Following completion of the Part B 36-week treatment period and 16-week off-drug follow-up period, eligible patients can enroll in an OLE. Enrollment and dosing remain ongoing in the OLE. Analysis from the Part B 16-week off-drug follow-up period and OLE will inform the bempikibart long-term chronic maintenance regimen, which could include monthly, bi-monthly or quarterly dosing, which will be evaluated in future studies. Q32 Bio anticipates data from the Part B OLE in the second half of 2027.
Q32 Bio plans to advance bempikibart into a registration-directed program for patients with severe or very severe AA in the first half of 2027 subject to planned regulatory discussions in the second half of 2026. Additionally, based on results observed, Q32 Bio is evaluating opportunities for bempikibart in expanded AA populations as well as in other autoimmune and inflammatory indications.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.